logo
Share SHARE
FONT-SIZE Plus   Neg

Earnings Watch For April 10 (AA, SVU)

Alcoa, Inc. (AA) will set the tone for corporate earnings season today. The aluminum producer, the first component of the Dow Jones Industrial Average to announce its quarterly results, is expected to report a loss of $0.04 per share on revenues of $5.77 billion for the first quarter. A year earlier, earnings and revenue were $0.28 per share and $5.96 billion respectively. Higher pricing, growing demand in major end markets and improved productivity positively affected the year-ago results. On the NYSE, AA closed Monday's regular trade at $9.60. (The stock gained nearly 16% in Q1; MA(50)- $10.20; MA(100)- $9.85; 52-wk H/L $17.96/$8.45)

Grocery retailer Supervalu Inc. (SVU) is expected to report results for the fourth quarter. The company is expected to earn $0.35 per share on revenues of $8.31 billion. In the same quarter a year earlier, the company reported earnings of $0.44 per share on revenues of $8.66 billion. The shares closed Monday at $5.32. (The stock plunged almost 29% in Q4; MA(50)- $6.41; MA(100)- $7.00; 52-wk H/L $11.77/$5.07)

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT